Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history.
Jin Hwa KimYoung Sang LyuBongSeong KimMee Kyoung KimSang Yong KimKi-Hyun BaekKi-Ho SongKyung Do HanHyuk-Sang KwonPublished in: Diabetes, obesity & metabolism (2024)
The initiation of SGLT2 inhibitors in patients with type 2 diabetes and a history of PCI was significantly associated with a reduced risk of cardiorenal consequences and mortality, irrespective of time since the last PCI.
Keyphrases
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- coronary artery disease
- type diabetes
- coronary artery bypass grafting
- cardiovascular events
- atrial fibrillation
- glycemic control
- cardiovascular disease
- coronary artery bypass
- insulin resistance
- heart failure
- risk factors
- adipose tissue